Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06853912 · ClinicalTrials.gov registry record · Phase 2
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
A Phase 2 study of PTSD and Alcohol Use Disorder (AUD), sponsored by Nathan Brashares Sackett.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06853912: Recruiting Phase 2 study of PTSD and Alcohol Use Disorder (AUD), sponsored by Nathan Brashares Sackett.
NCT06853912 is a Phase 2 study of PTSD and Alcohol Use Disorder (AUD) that is actively recruiting participants, run by Nathan Brashares Sackett. The registered enrollment target is 40 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06853912, a Phase 2 study of PTSD and Alcohol Use Disorder (AUD), is actively recruiting participants, sponsored by Nathan Brashares Sackett.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD). Psychological support is defined as providing safety, reassurance, active listening, and empathetic presence during the drug administration session in a nondirective manner. We hypothesize that Psi-PS may provide a safe treatment for participants. The primary objective of study is to characterize the safety of psilocybin combined with psychological support (Psi-PS) for individuals with co-occurring alcohol use disorder (AUD) and PTSD.
Primary Outcome
Safety of Psi-PS will be measured through the assessment of adverse events (AEs), serious adverse events (SAEs), and acute suicidality using the Columbia Suicide Severity Rating Scale (C-SSRS).
Conditions Studied
Interventions
- DRUG Psilocybin 25 mg
- DRUG Maltodextrin (Placebo)
Study Locations (1)
Washington
- University of Washington Center for Novel Therapeutics in Addiction Psychiatry - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
What NCT06853912 shows while recruiting
NCT06853912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin 25 mg is the first listed.
NCT06853912 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06853912 about?
NCT06853912 is a clinical study titled "Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)". This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages ...
What is the current status of trial NCT06853912?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-06-01. Estimated completion is 2026-06-01.
What conditions does trial NCT06853912 study?
This clinical trial studies the following conditions: PTSD, Alcohol Use Disorder (AUD).
What interventions are being tested in trial NCT06853912?
The interventions under investigation include: Psilocybin 25 mg (DRUG), Maltodextrin (Placebo) (DRUG).
Who is sponsoring clinical trial NCT06853912?
This trial is sponsored by Nathan Brashares Sackett, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06853912 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06853912's enrollment target sits among peer trials
40 106th of 154 higher than 41 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
-
Intranasal Insulin for Posttraumatic Stress Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI